US limits use of J&J’s COVID vaccine on blood clot risks

A vial of the Johnson & Johnson’s coronavirus disease (COVID-19) vaccine is seen at Northwell Health’s South Shore University Hospital in Bay Shore, New York, US, March 3, 2021. REUTERS/Shannon Stapleton/File Photo

Register now for FREE unlimited access to

May 5 (Reuters) – The US health regulator said on Thursday it was limiting the use of Johnson & Johnson’s (JNJ.N) COVID-19 vaccine for adults due to the risk of a rare blood clotting syndrome, the latest setback to the shot that has been eclipsed by rivals.

The J&J shot, which received US clearance in February 2021 for adults, can be administered in cases where authorized or approved COVID-19 vaccines are not accessible or if an individual is less keen on using the other two shots, the Food and Drug Administration said .

J&J is one of the three vaccines in use in the United States. The other two are from Moderna (MRNA.O) and Pfizer (PFE.N).

Register now for FREE unlimited access to

The vaccine maker said it has updated the US COVID-19 vaccine fact sheet to warn about the risk of thrombosis with thrombocytopenia syndrome (TTS), a rare but potentially life-threatening condition.

Use of the J&J shot has been weak in high-income countries, hurt by reports of rare, potentially deadly blood clots, production issues, including an accidental mix-up of ingredients by a contract manufacturer, and concerns about efficacy.

The drugmaker last month rescinded its forecast for COVID-19 vaccine sales, citing a glut of supply. read more

Cases of TTS, which involves blood clots accompanied by a low level of platelets, have previously been reported in recipients of the J&J vaccine.

The FDA in January amended the fact sheet for the J&J vaccine to include the risk of immune thrombocytopenia, months after the European Union’s drug regulator took similar action.

The FDA on Thursday said the risk of TTS warranted limiting the use of the single-dose shot after it conducted investigation of reported cases.

The US Centers for Disease Control and Prevention in December had recommended that Americans choose to receive mRNA shots from Pfizer and Moderna over J&J’s vaccine due to the rare cases of blood clotting. read more

Around 18.7 million Americans have received a J&J COVID-19 shot compared with 217.5 million people who received the Moderna vaccine and 340.6 million people who received Pfizer’s shot, according to the CDC.

Register now for FREE unlimited access to

Reporting by Amruta Khandekar; Additional reporting by Rhea Binoy; Editing by Anil D’Silva, Shailesh Kuber and Uttaresh.V

Our Standards: The Thomson Reuters Trust Principles.


Leave a Comment

Your email address will not be published.